Immunological methods of treating cancer

Abstract

A drug, affecting the hyperactivated immunologic effector cells, comprising (I) a Ca-antagonist and (II) an agent, reducing the intracellular cAMP/cGMP-ratio, is being described. In addition, a drug, affecting the hyperactivated immunologic effector cells, consisting of (I) an agent, eliminating the hyperactivated effector cells and (II) alloreactive cells with predetermined cell death, is being described.

1 . Drugs, affecting hyperactivated immunologic effector cells, consisting of (I) a Ca-antagonist, and (II) an agent, reducing the intracellular cAMP/cGMP-ratio.  
     
     
         2 . Drugs, according to the  claim 1 , specified by the fact that Ca-antagonist is a Ca-overload-blocker.  
     
     
         3 . Drugs, according to the  claim 1  or  2 , specified by the fact that Ca-antagonist is-cinnarizine.  
     
     
         4 . Drugs, according to one of the preceding claims, specified by the fact that component (II) is a drug which decreases the cAMP-level in the cell and/or a drug which increases the cGMP-level.  
     
     
         5 . Drugs, according to the  claim 4 , specified by the fact that the cAMP level-decreasing drug is an antagonist of Gs-coupled receptors and/or an antagonist of Gi/Gp/Go-coupled receptors.  
     
     
         6 . Drugs, according to the claims  4  or  5 , specified by the fact that component (II) is an antagonist of B-adrenergic receptors, histamine receptors and/or A2-purinergic receptors.  
     
     
         7 . Drugs, according to the  claim 6 , specified by the fact that the antagonist of B-adrenergic receptors is propranolol.  
     
     
         8 . Drugs, affecting hyperactivated immunologic effector cells, comprising (I) an agent, eliminating hyperactivated effector cells, and (II) alloreactive cells with a preprogrammed cell death.  
     
     
         9 . Drugs, according to the  claim 8 , specified by the fact that component (I) is a T cell-depleting agent.  
     
     
         10 . Drugs, according to the  claim 9 , specified by the fact that complement (I) comprises antibodies, directed against CD8 and/or CD3.  
     
     
         11 . Drugs, according to one of the  claims 8  to  10 , specified by the fact that component(I) contains in addition a cytotoxic agent, especially cyclophosphamide.  
     
     
         12 . Drugs, according to the  claims 8  to  11 , specified by the fact that component (II) comprises allogeneic cells whose DNA was manipulated in a controlled way and which are able to inactivate the pathologic Ts cells and/or hyperactivated macrophages.  
     
     
         13 . The use of a combination of a Ca-antagonist and a drug, able to reduce the intracellular cAMP/cGMP-ratio, to produce a drug for the treatment of cancer, viral and bacterial infections and autoimmune disorders.  
     
     
         14 . The use of a combination, consisting of an agent, eliminating the hyperactivated effector cells, and of alloreactive cells with the preprogrammed cell death to produce a drug for the treatment of cancer, viral infections and autoimmune diseases.  
     
     
         15 . Procedure for the treatment of cancer, viral infections and autoimmune disorders, based on the elimination of hyperactivated immunological effector cells or their down-regulation to the normal state which enables the patient's immune response to restore the pre-disease state.